KB7.F Solventum Corporation
- Market cap
- EUR 13.4B
- P/E
- 102.6x
- P/B
- 3.17x
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KB7.F undervalued?
Graham numberThe Graham number of Solventum Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solventum Corporation fundamental analysis
No fundamental analysis for Solventum Corporation yet.
Solventum Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, steriliz…
Full company profileSolventum Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solventum Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 8.17B | 8.13B | 8.20B | 8.25B | 8.33B | 8.22B |
| Gross Profit | 4.92B | 4.70B | 4.69B | 4.59B | 4.45B | 4.59B |
| Operating Income | 1.88B | 1.69B | 1.64B | 1.04B | 632M | 437M |
| EBITDA | - | 2.27B | 2.23B | 1.53B | 2.55B | 948M |
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B | 124M |
| EPS | 8.45 | 7.78 | 7.79 | 2.77 | 8.97 | 0.73 |
| Balance Sheet | ||||||
| Total Assets | 14.1B | 13.6B | 13.9B | 14.5B | 14.3B | 14.2B |
| Total Liabilities | 2.02B | 1.85B | 2.28B | 11.5B | 9.24B | 9.36B |
| Shareholders' Equity | 12.1B | 11.7B | 11.7B | 2.96B | 5.05B | 4.81B |
| Cash & Short-term Investments | 91.0M | 61.0M | 194M | 762M | 878M | 451M |
| Cash Flow | ||||||
| Operating Cash Flow | 2.20B | 1.68B | 1.92B | 1.19B | 369M | 287M |
| Capital Expenditure | 277M | 251M | 290M | 380M | 379M | 329M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | -10.0M | -42.7M |
| Ratios | ||||||
| ROE | 12.1% | 11.4% | 11.5% | 16.2% | 30.8% | 2.6% |
| ROA | 10.4% | 9.9% | 9.7% | 3.3% | 10.9% | 0.9% |
| Net Profit Margin | 17.9% | 16.5% | 16.4% | 5.8% | 18.7% | 1.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Solventum Corporation dividends
Solventum Corporation has not paid dividends in the last 5 fiscal years.
Who owns Solventum Corporation
- Insiders 15.38%
- Institutions 76.13%
- Public & others 8.49%
- Shares outstanding 170M
- Free float 144M
Solventum Corporation company profile
- Company name
- Solventum Corporation
- Ticker
- KB7.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 20,584
- Fiscal year end
- December
- Address
- 1750 Yankee Doodle Road, Eagan, MN, United States, 55121
- Phone
- (651) 733-1110
- Website
- solventum.com
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Solventum Corporation management
10- Mr. Bryan C. HansonCEO & Director · born 1967
- Mr. Wayde D. McMillanExecutive VP & CFO · born 1970
- Ms. Amy LanducciChief Information & Digital Officer · born 1975
- Ms. Marcela A. KirbergerChief Corporate & Legal Affairs Officer & Corporate Secretary · born 1967
- Ms. Heather L. KnightChief Commercial Officer · born 1972
- Mr. Neil C. ZieselmanSenior VP, Controller & Chief Accounting Officer · born 1976
- Ms. Amy WakehamSenior Vice President of Investor Relations & External Finance Communications
- Ms. Rachel H. EllingsonChief Strategy & Corporate Development Officer · born 1970
- Ms. Tammy L. GomezChief Human Resources Officer · born 1973
- Mr. Paul S. HarringtonChief Supply Chain Officer · born 1970